4142:TPE
Adimmune Corp
15,85Â TWD
arrow_downward
−1,86%(−0,30) 1 D
19. nov., 13:30:08 GMT+8 · TWD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 4142 …
Ã…pne
16,20Â TWD
Høy
16,25Â TWD
Lav
15,70Â TWD
Markedsverdi
6,81Â mrd.
Snittvolum
1,09Â mill.
Volum
1,60Â mill.
P/E-forhold
91,85
52 u høy
21,50Â TWD
52Â u lav
15,65Â TWD
EPS
0,17Â TWD
Utestående aksjer
235,29Â mill.
Antall ansatte
564
Ã…pne
16,20Â TWD
Høy
16,25Â TWD
Lav
15,70Â TWD
Markedsverdi
6,81Â mrd.
Snittvolum
1,09Â mill.
Volum
1,60Â mill.
P/E-forhold
91,85
52 u høy
21,50Â TWD
52Â u lav
15,65Â TWD
EPS
0,17Â TWD
Utestående aksjer
235,29Â mill.
Antall ansatte
564
Nyhetssaker
Fra nettkilder og nyhetspartnere
Business Insider
·
for 47 minutter siden
Why Morgan Stanley Says the S&P 500 Is Poised to Jump 18%
The Motley Fool
·
for 1 time siden
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
Pittsburgh Post-Gazette
·
for 19 timer siden
A fifth straight drop for the S&P 500 drags Wall Street to its longest losing streak since June
Hedgeye
·
for 21 timer siden
Why Negative Gamma Has Taken the Brakes Off the S&P 500
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Om Adimmune Corp
Administrerende direktør-
Ansatte564
Grunnlagt1965
Hovedkontor-
SektorHealth Care
Bransje-
Nettstedadimmune.com.tw